The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The safety and efficacy of tisa-cel for R/R DLBCL in real-world settings
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on preliminary findings from the European post-authorisation safety study on tisagenlecleucel (tisa-cel) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). He highlights similar findings between real-world data and and the registration trial, demonstrating the safety and efficacy of the treatment in diverse clinical settings. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
